M R Emmerling

Summary

Affiliation: Parke-Davis Pharmaceutical Research
Country: USA

Publications

  1. ncbi request reprint Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury
    M R Emmerling
    Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Ann N Y Acad Sci 903:118-22. 2000
  2. ncbi request reprint The role of complement in Alzheimer's disease pathology
    M R Emmerling
    Neuroscience Therapeutics, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48106, USA
    Biochim Biophys Acta 1502:158-71. 2000
  3. ncbi request reprint Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein
    M R Emmerling
    Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, MI 48106
    Biochem Biophys Res Commun 197:292-7. 1993
  4. ncbi request reprint Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide
    M R Emmerling
    Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Department of Pharmacology, Neuroscience Therapeutics, Ann Arbor, MI 48105, USA
    Immunopharmacology 38:101-9. 1997
  5. ncbi request reprint The role of arachidonic acid in the secretion of the amyloid precursor protein (APP)
    M R Emmerling
    Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, Michigan 48106, USA
    Ann N Y Acad Sci 777:310-5. 1996

Detail Information

Publications5

  1. ncbi request reprint Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury
    M R Emmerling
    Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Ann N Y Acad Sci 903:118-22. 2000
    ..Inflammation and alterations in BBB may play lesser, but nonetheless significant, roles in determining the A beta level in CSF after brain injury...
  2. ncbi request reprint The role of complement in Alzheimer's disease pathology
    M R Emmerling
    Neuroscience Therapeutics, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48106, USA
    Biochim Biophys Acta 1502:158-71. 2000
    ..Pharmacology therapies that may serve to inhibit Abeta-mediated complement activation will also be discussed...
  3. ncbi request reprint Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein
    M R Emmerling
    Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, MI 48106
    Biochem Biophys Res Commun 197:292-7. 1993
    ..These results implicate PLA2 in regulating APP processing and secretion, which may have important implications for understanding the pathogenesis of Alzheimer's Disease...
  4. ncbi request reprint Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide
    M R Emmerling
    Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Department of Pharmacology, Neuroscience Therapeutics, Ann Arbor, MI 48105, USA
    Immunopharmacology 38:101-9. 1997
    ..Our results provide further evidence that aggregated A beta 1-42 alone is sufficient to serve as a nidus for complement activation, and thus may be involved directly in initiating the inflammation seen in AD brains...
  5. ncbi request reprint The role of arachidonic acid in the secretion of the amyloid precursor protein (APP)
    M R Emmerling
    Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, Michigan 48106, USA
    Ann N Y Acad Sci 777:310-5. 1996
    ..Moreover, activation of PLA2 appears to be an obligatory event in increasing the secretion of APP from CHO-ml cells by the various methods of activation that we have tried thus far...